REGN
Regeneron·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 2
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
High Cash/net Profit Ratio
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About REGN
Regeneron Pharmaceuticals, Inc.
A company that developing drugs to treat eye diseases, inflammatory diseases and cancer
777 Old Saw Mill River Road, Tarrytown, NewYork 10591-6707
Production and sales of pharmaceutical products
Regeneron Pharmaceuticals, Inc. was founded in New York State in 1988. Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company that discovers, invents, develops, manufactures and commercializes drugs for the treatment of serious diseases. Its commercialized drugs and product candidates under development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases. Its core business strategy is to maintain a solid foundation in basic scientific research and discovery enabling technologies, and build on clinical development, manufacturing and commercial capabilities. Its goal is to continue to be a comprehensive, multi-product biotechnology company that provides patients and medical professionals with important options for the prevention and treatment of human diseases.
Earnings Call
Q2/2025
Estimate EPS8.44
Actual EPS12.89
Estimate Revenue3.28B
Actual Revenue3.68B
Regeneron's 2025 Q2 Earnings Call: Key Contradictions in EYLEA HD Issues, Patient Assistance, and Pricing Strategy
Aug 01,2025 02:01
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS9.64
Actual EPS11.83
Estimate Revenue3.59B
Actual Revenue3.75B
Regeneron's Q3 2025 Earnings Call: Contradictions Emerge on Eylea Demand, Manufacturing, and Factor Xi Prioritization
Oct 28,2025 01:50
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
REGN has released its 2025 Q3 earnings. EPS was reported at 11.83, versus the expected 9.64, beating expectations. The chart below visualizes how REGN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
REGN has released its 2025 Q3 earnings report, with revenue of 3.75B, reflecting a YoY change of 0.90%, and net profit of 1.46B, showing a YoY change of 8.91%. The Sankey diagram below clearly presents REGN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
